Tonix Pharmaceuticals Holding Corp (LTS:0A4T)
$ 134.6 0 (0%) Market Cap: 17.80 Mil Enterprise Value: 12.04 Mil PE Ratio: 0 PB Ratio: 0.40 GF Score: 31/100

Tonix Pharmaceuticals Holding Corp at Q2 Investor Summit Transcript

May 04, 2022 / 03:00PM GMT
Release Date Price: $134.6
Jessica Morris
Tonix Pharmaceuticals - COO

Thank you. Welcome everyone today to Tonix's presentation in the room today in person and also online with the webcast. I'm happy to be presenting today on behalf of Tonix. I am the Chief Operating Officer, Jessica Morris. So we are a publicly traded company on NASDAQ under the ticker TNXP. I will be making forward-looking statements as part of this presentation. So I would refer you to our SEC filings for complete information.

So Tonix Pharmaceuticals is a clinical stage biopharmaceutical company, and our mission is to advance the science and understanding of diseases by developing new therapies for health improvement of our population by focusing on unmet needs. And how do we do this? Our strategy is to use what we call our integrated development engine, our team of experienced professionals in preclinical, clinical, regulatory, CMC areas, all working together to take products from preclinical stage for development with the goal of FDA approval.

So these next few slides are Tonix's pipeline, and we have a broad pipeline. This is one of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot